ArticleDrug design, development and therapy2014
Omalizumab, an anti-immunoglobulin E antibody: state of the art.
Article in Drug design, development and therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 55 citations in OpenAlex.
- Omalizumab for the reduction of allergic reactions to foods: a narrative review.Frontiers in allergy · 2024Review
- The Role ofInternational journal of molecular sciences · 2022Review
- Effects of omalizumab on allergic conjunctivitis.International ophthalmology · 2022Article
- Suppression of IgE-mediated anaphylaxis and food allergy with monovalent anti-FcεRIα mAbs.The Journal of allergy and clinical immunology · 2021Article
- Adrenal insufficiency is a contraindication for omalizumab therapy in mast cell activation disease: risk for serum sickness.Naunyn-Schmiedeberg's archives of pharmacology · 2020Review
- Rapid desensitization of humanized mice with anti-human FcεRIα monoclonal antibodies.The Journal of allergy and clinical immunology · 2020Article
- Successful treatment of idiopathic mast cell activation syndrome with low-dose Omalizumab.Clinical & translational immunology · 2019Article
- The Intersection of IgE Autoantibodies and Eosinophilia in the Pathogenesis of Bullous Pemphigoid.Frontiers in immunology · 2019Review
- The effect of omalizumab treatment on severe allergic asthma and allergic comorbidities: real-life experience from the Czech Anti-IgE Registry.Postepy dermatologii i alergologii · 2018Article
- Immunoglobulin G; structure and functional implications of different subclass modifications in initiation and resolution of allergy.Immunity, inflammation and disease · 2018Review
- Eosinophils from Physiology to Disease: A Comprehensive Review.BioMed research international · 2018Review
- Evolution of anti-IgE treatment.Cellular & molecular immunology · 2016Article
- IgE-Related Chronic Diseases and Anti-IgE-Based Treatments.Journal of immunology research · 2016Review
- Omalizumab for difficult-to-treat dermatological conditions: clinical and immunological features from a retrospective real-life experience.Clinical drug investigation · 2015Article
- Omalizumab in children.Paediatric drugs · 2014Review
- Burden and distinctive character of allergic bronchopulmonary aspergillosis in India.Mycopathologia · 2014Review
- Acute Interstitial Nephritis: A Rare and Unusual Side Effect of Omalizumab.Journal of investigative medicine high impact case reportsArticle
- Shifting Focus in the Therapeutics of Immunobullous Disease.Indian journal of dermatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A large number of trials show that the anti-immunoglobulin (Ig) E antibody omalizumab is very effective in patients with severe allergic asthma. This is acknowledged in consensus documents. The drug also has a good safety profile and a pharmacoeconomic advantage due to a reduction in the number of hospitalizations for asthma attacks. In recent years, some studies have shown that omalizumab is effective also in nonallergic asthma. Effects on the complex signaling mechanisms leading to activation of effector cells and to mediator release may account for this outcome. Indeed, omalizumab has been reported to be effective in a number of IgE-mediated and non-IgE-mediated disorders. Concerning the former, clinical efficacy has been observed in rhinitis, allergic bronchopulmonary aspergillosis, latex allergy, atopic dermatitis, allergic urticaria, and anaphylaxis. In addition, omalizumab has been demonstrated to be able to prevent systemic reactions to allergen immunotherapy, thus enabling completion of treatment in patients who otherwise would have to stop it. Concerning non-IgE-mediated disorders, omalizumab has been reported to be effective in nasal polyposis, autoimmune urticaria, chronic idiopathic urticaria, physical urticaria, idiopathic angioedema, and mastocytosis. Current indications for treatment with omalizumab are confined to severe allergic asthma. Consequently, any other prescription can only be off-label. However, it is reasonable to expect that the use of omalizumab will be approved for particularly important indications, such as anaphylaxis, in the near future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.